nogrЭкспериментальная и клиническая гастроэнтерологияExperimental and Clinical Gastroenterology1682-8658«Global Media Technologies»10.31146/1682-8658-ecg-212-4-121-132nogr-2371Research ArticleОБЗОРREVIEWЗначимость уровней сывороточных маркеров для оценки статуса и прогноза больных с воспалительными заболеваниями кишечникаThe significance of serum marker levels for assessing the status and prognosis of patients with inflammatory bowel diseasehttps://orcid.org/0000-0003-0077-3823КручининаМ. В.KruchininaM. V.kruchmargo@yandex.ruСветловаИ. О.SvetlovaI. O.noemail@neicon.ruhttps://orcid.org/0000-0002-5156-2842ОсипенкоМ. Ф.OsipenkoM. F.noemail@neicon.ruАбалтусоваН. В.AbaltusovaN. V.noemail@neicon.ruhttps://orcid.org/0000-0001-9254-4192ГромовА. А.GromovA. A.noemail@neicon.ruБорисоваА. В.BorisovaA. V.noemail@neicon.ruКручининаЭ. В.KruchininaE. V.noemail@neicon.ruНаучно-исследовательский институт терапии и профилактической медицины - филиал Федерального государственного бюджетного научного учреждения «Федеральный исследовательский центр Институт цитологии и генетики Сибирского отделения Российской академии наук»; Федеральное государственное бюджетное образовательное учреждение высшего образования «Новосибирский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияResearch Institute of Internal and Preventive Medicine- branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences; Novosibirsk State Medical UniversityRussian FederationФедеральное государственное бюджетное образовательное учреждение высшего образования «Новосибирский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияNovosibirsk State Medical UniversityRussian FederationООО «ЕВРОМЕДКЛИНИКА»РоссияLLC “EUROMEDKLINIKA”Russian FederationНаучно-исследовательский институт терапии и профилактической медицины - филиал Федерального государственного бюджетного научного учреждения «Федеральный исследовательский центр Институт цитологии и генетики Сибирского отделения Российской академии наук»РоссияResearch Institute of Internal and Preventive Medicine- branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of SciencesRussian Federation20232607202304121132Copyright © Кручинина М.В., Светлова И.О., Осипенко М.Ф., Абалтусова Н.В., Громов А.А., Борисова А.В., Кручинина Э.В., 20232023Кручинина М.В., Светлова И.О., Осипенко М.Ф., Абалтусова Н.В., Громов А.А., Борисова А.В., Кручинина Э.В.Kruchinina M.V., Svetlova I.O., Osipenko M.F., Abaltusova N.V., Gromov A.A., Borisova A.V., Kruchinina E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nogr.org/jour/article/view/2371

Цель работы: провести анализ исследований, выполненных в последнее десятилетие, посвященных изучению сывороточных маркеров, используемых для диагностики воспалительных заболеваний кишечника (ВЗК), дифференциальной диагностики нозологических форм ВЗК, для прогнозирования течения заболевания, ответа на проводимую терапию, а также предикции рецидива заболевания. Материалы и методы. Проведен поиск с использованием ключевых слов в текстовых базах данных “Scopus”, “Web of Science”, “PubMed” по литературным источникам последних 10 лет о биомаркерах сыворотки крови, используемых для диагностики, оценки терапевтической эффективности, мониторинга за активностью заболевания и оценки прогноза при ВЗК. Результаты. Проанализирована информация о серологических биомаркерах ВЗК, которые хорошо известны и широко используются в клинической практике (С-реактивный белок), недавно открытых биомаркерах (цитокины, антитела и некодирующие РНК), а также последних достижениях в области поиска серологических биомаркеров (метаболомика, протеомика, онкостатин М, галектины), которые используются в различных аспектах диагностики ВЗК. Поскольку фиброз кишечника заметно влияет на прогноз у пациентов с ВЗК, отдельно представлены данные о сывороточных маркерах фиброза кишечника. Заключение. В последнее время биомаркеры сыворотки у пациентов с ВЗК стали объектом пристального внимания, поскольку они малоинвазивны, удобны и относительно недороги по сравнению с маркерами в биоптатах, других биологических жидкостях, фекальными и дыхательными тестами. Несмотря на множество исследований, проведенных в последние 10 лет, до сих пор не существует идеальных сывороточных биомаркеров для диагностики ВЗК. Методы профилирования сыворотки и определения некодирующих РНК только начинают развиваться, но открывают большие перспективы для клинической практики. Сочетание различных биомаркеров может быть полезным для повышения эффективности диагностики ВЗК.

Purpose of the work: to analyze the research performed in the last decade on the study of serum markers used to diagnose inflammatory bowel diseases (IBD), differential diagnosis of nosological forms of IBD, to predict the course of the disease, response to ongoing therapy, as well as to predict the recurrence of the disease. Materials and methods. A search was carried out in the text databases “Scopus”, “Web of Science”, “PubMed” using keywords from the literature sources of the last 10 years about blood serum biomarkers used for diagnosis, evaluation of therapeutic efficacy, monitoring of disease activity and evaluation of prognosis in patients with IBD. Results. Information on serological biomarkers of IBD, which are well known and widely used in clinical practice (C-reactive protein), recently discovered biomarkers (cytokines, antibodies and non-coding RNA), as well as recent advances in serological biomarkers (metabolomics, proteomics, oncostatin M, galectins), were analyzed, which are used in various aspects of the diagnosis of IBD. Since intestinal fibrosis significantly affects the prognosis in patients with IBD, data on serum markers of intestinal fibrosis are presented separately. Conclusion. Recently, serum biomarkers in patients with IBD have become the object of close attention, since they are minimally invasive, convenient, and relatively inexpensive than markers in biopsy specimens, other biological fluids, fecal, and respiratory tests. Despite an extensive list of studies conducted over the past 10 years, there are still no ideal serum biomarkers for the diagnosis of IBD. Serum and non-coding RNA profiling techniques are just beginning to develop, but offer great promise for clinical practice. A combination of different biomarkers may be useful to improve the efficiency of IBD diagnosis.

воспалительные заболевания кишечникасывороточные маркерыдифференциальная диагностика активность заболеванияпрогнозinflammatory bowel diseaseserum markersdifferential diagnosisdisease activityprognosisReferencesKaplan G.G., Ng S. C. Understanding and preventing the global increase of in ammatory bowel disease. Gastroenterology. 2017; 152:313-21. doi: 10.1053/j.gastro.2016.10.020Kaplan G.G., Ng S. C. Understanding and preventing the global increase of in ammatory bowel disease. Gastroenterology. 2017; 152:313-21. doi: 10.1053/j.gastro.2016.10.020Kaplan G. G., Ng S. C. Understanding and preventing the global increase of in ammatory bowel disease. Gastroenterology. 2017 Feb;152(2):313-321.e2. doi: 10.1053/j.gastro.2016.10.020.Kaplan G. G., Ng S. C. Understanding and preventing the global increase of in ammatory bowel disease. Gastroenterology. 2017 Feb;152(2):313-321.e2. doi: 10.1053/j.gastro.2016.10.020.Gomollón F., Dignass A., Annese V. et al. European evidence-based consensus on the diagnosis and management of Crohn’s Disease 2016: part 1: diagnosis and Medical Management. J Crohn’s Colitis. 2016; 11:3-25. doi: 10.1093/ecco-jcc/jjw168.Gomollón F., Dignass A., Annese V. et al. European evidence-based consensus on the diagnosis and management of Crohn’s Disease 2016: part 1: diagnosis and Medical Management. J Crohn’s Colitis. 2016; 11:3-25. doi: 10.1093/ecco-jcc/jjw168.Vermeire S. Laboratory Markers in IBD: Useful, Magic, or Unnecessary Toys? Gut. 2006; 55:426-31. doi: 10.1136/gut.2005.069476.Vermeire S. Laboratory Markers in IBD: Useful, Magic, or Unnecessary Toys? Gut. 2006; 55:426-31. doi: 10.1136/gut.2005.069476.Rump J.A., Schölmerich J., Gross V., et al. A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn’s disease. Immunobiology. 1990 Nov;181(4-5):406-13. doi: 10.1016/S0171-2985(11)80509-7.Rump J.A., Schölmerich J., Gross V., et al. A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn’s disease. Immunobiology. 1990 Nov;181(4-5):406-13. doi: 10.1016/S0171-2985(11)80509-7.Smids C., Horjus T. H.C., Groenen M. et al. The value of serum antibodies in di erentiating in ammatory bowel disease, predicting disease activity and disease course in the newly diagnosed patient. Scand J Gastroenterol. 2017; 52:1104-12. doi: 10.1080/00365521.2017.1344875.Smids C., Horjus T. H.C., Groenen M. et al. The value of serum antibodies in di erentiating in ammatory bowel disease, predicting disease activity and disease course in the newly diagnosed patient. Scand J Gastroenterol. 2017; 52:1104-12. doi: 10.1080/00365521.2017.1344875.Peeters M., Joossens S., Vermeire S. et al. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in in ammatory bowel disease. Am J Gastroenterol. 2001; 96:730-4. doi: 10.1111/j.1572-0241.2001.03613.x.Peeters M., Joossens S., Vermeire S. et al. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in in ammatory bowel disease. Am J Gastroenterol. 2001; 96:730-4. doi: 10.1111/j.1572-0241.2001.03613.x.Schulte-Pelkum J., Radice A., Norman G. L. et al. Novel clinical and diagnostic aspects of antineutrophil cytoplasmic antibodies. J Immunol Res. 2014; 2014:185416. doi: 10.1155/2014/185416.Schulte-Pelkum J., Radice A., Norman G. L. et al. Novel clinical and diagnostic aspects of antineutrophil cytoplasmic antibodies. J Immunol Res. 2014; 2014:185416. doi: 10.1155/2014/185416.Vasseur F., Sendid B., Jouault T. et al. Variants of NOD1 and NOD2 genes display opposite associations with familial risk of Crohn’s disease and anti-saccharomyces cerevisiae antibody levels. In amm Bowel Dis. 2012; 18:430-8. doi: 10.1002/ibd.21817.Vasseur F., Sendid B., Jouault T. et al. Variants of NOD1 and NOD2 genes display opposite associations with familial risk of Crohn’s disease and anti-saccharomyces cerevisiae antibody levels. In amm Bowel Dis. 2012; 18:430-8. doi: 10.1002/ibd.21817.Vasiliauskas E.A., Kam L. Y., Karp L. C., Gaiennie J., Yang H., Targan S. R. Marker antibody expression stratifies Crohn’s disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut. 2000 Oct;47(4):487-96. doi: 10.1136/gut.47.4.487.Vasiliauskas E.A., Kam L. Y., Karp L. C., Gaiennie J., Yang H., Targan S. R. Marker antibody expression stratifies Crohn’s disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut. 2000 Oct;47(4):487-96. doi: 10.1136/gut.47.4.487.Prideaux L., Kamm M. A., De Cruz P. et al. In ammatory bowel disease serology in Asia and the West. World J Gastroenterol. 2013; 19:6207-13. doi: 10.3748/wjg.v19.i37.6207.Prideaux L., Kamm M. A., De Cruz P. et al. In ammatory bowel disease serology in Asia and the West. World J Gastroenterol. 2013; 19:6207-13. doi: 10.3748/wjg.v19.i37.6207.Lee W.I., Subramaniam K., Hawkins C. A., Randall K. L. The signi cance of ANCA positivity in patients with in ammatory bowel disease. Pathology. 2019; 51:634-9. doi: 10.1016/j.pathol.2019.07.002.Lee W.I., Subramaniam K., Hawkins C. A., Randall K. L. The signi cance of ANCA positivity in patients with in ammatory bowel disease. Pathology. 2019; 51:634-9. doi: 10.1016/j.pathol.2019.07.002.Komorowski L., Teegen B., Probst C. et al. Autoantibodies against exocrine pancreas in Crohn’s disease are directed against two antigens: the glycoproteins CUZD1 and GP2. J Crohns Colitis. 2013; 7:780-90. doi: 10.1016/j.crohns.2012. 10.011.Komorowski L., Teegen B., Probst C. et al. Autoantibodies against exocrine pancreas in Crohn’s disease are directed against two antigens: the glycoproteins CUZD1 and GP2. J Crohns Colitis. 2013; 7:780-90. doi: 10.1016/j.crohns.2012. 10.011.Ohno H., Hase K. Glycoprotein 2 (GP2): grabbing the FimH bacteria into M cells for mucosal immunity. Gut Microbes. 2010; 1:407-10. doi: 10.4161/gmic.1.6.14078.Ohno H., Hase K. Glycoprotein 2 (GP2): grabbing the FimH bacteria into M cells for mucosal immunity. Gut Microbes. 2010; 1:407-10. doi: 10.4161/gmic.1.6.14078.Werner L., Paclik D., Fritz C. et al. Identi cation of pancreatic glycoprotein 2 as an endogenous immunomodulator of innate and adaptive immune responses. J Immunol. 2012; 189:2774-83. doi: 10.4049/jimmunol.1103190.Werner L., Paclik D., Fritz C. et al. Identi cation of pancreatic glycoprotein 2 as an endogenous immunomodulator of innate and adaptive immune responses. J Immunol. 2012; 189:2774-83. doi: 10.4049/jimmunol.1103190.Pavlidis P., Romanidou O., Roggenbuck D. et al. Ileal in ammation may trigger the development of GP2- speci c pancreatic autoantibodies in patients with Crohn’s disease. Clin Dev Immunol. 2012; 2012:640835. doi: 10.1155/2012/640835.Pavlidis P., Romanidou O., Roggenbuck D. et al. Ileal in ammation may trigger the development of GP2- speci c pancreatic autoantibodies in patients with Crohn’s disease. Clin Dev Immunol. 2012; 2012:640835. doi: 10.1155/2012/640835.Bogdanos D.P., Roggenbuck D., Reinhold D. et al. Pancreatic-speci c autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn’s disease. BMC Gastroenterol. 2012; 12:102. doi: 10.1186/1471-230X-12-102.Bogdanos D.P., Roggenbuck D., Reinhold D. et al. Pancreatic-speci c autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn’s disease. BMC Gastroenterol. 2012; 12:102. doi: 10.1186/1471-230X-12-102.Pavlidis P., Shums Z., Koutsoumpas A. L. et al. Diagnostic and clinical signi cance of Crohn’s disease-speci c anti-MZGP2 pancreatic antibodies by a novel ELISA. Clin Chim Acta. 2015; 441:176-81. doi: 10.1016/j.cca.2014.12.010.Pavlidis P., Shums Z., Koutsoumpas A. L. et al. Diagnostic and clinical signi cance of Crohn’s disease-speci c anti-MZGP2 pancreatic antibodies by a novel ELISA. Clin Chim Acta. 2015; 441:176-81. doi: 10.1016/j.cca.2014.12.010.Somma V., Ababneh H., Ababneh A. et al. The novel Crohn’s disease marker anti-GP2 antibody is associated with ileocolonic location of disease. Gastroenterol Res Pract. 2013; 2013:683824. doi: 10.1155/2013/683824.Somma V., Ababneh H., Ababneh A. et al. The novel Crohn’s disease marker anti-GP2 antibody is associated with ileocolonic location of disease. Gastroenterol Res Pract. 2013; 2013:683824. doi: 10.1155/2013/683824.Roggenbuck D., Reinhold D., Werner L. et al. Glycoprotein 2 antibodies in Crohn’s disease. Adv Clin Chem. 2013; 60:187-208. doi: 10.1016/B978-0-12-407681-5.00006-4.Roggenbuck D., Reinhold D., Werner L. et al. Glycoprotein 2 antibodies in Crohn’s disease. Adv Clin Chem. 2013; 60:187-208. doi: 10.1016/B978-0-12-407681-5.00006-4.Michaels M.A., Jendrek S. T., Korf T. et al. Pancreatic autoantibodies against CUZD1 and GP2 are associated with distinct clinical phenotypes of Crohn’s disease. In amm Bowel Dis. 2015; 21:2864-72. doi: 10.1097/MIB.0000000000000564.Michaels M.A., Jendrek S. T., Korf T. et al. Pancreatic autoantibodies against CUZD1 and GP2 are associated with distinct clinical phenotypes of Crohn’s disease. In amm Bowel Dis. 2015; 21:2864-72. doi: 10.1097/MIB.0000000000000564.Gross S., Bakker S. F., van Bodegraven A. A. et al. Increased IgA glycoprotein-2 speci c antibody titres in refractory celiac disease. J Gastrointestin Liver Dis. 2014; 23:127-33. doi: 10.15403/jgld.2014.1121. 232.sg1.Gross S., Bakker S. F., van Bodegraven A. A. et al. Increased IgA glycoprotein-2 speci c antibody titres in refractory celiac disease. J Gastrointestin Liver Dis. 2014; 23:127-33. doi: 10.15403/jgld.2014.1121. 232.sg1.Tornai T., Tornai D., Sipeki N. et al. Loss of tolerance to gut immunity protein, glycoprotein 2 (GP2) is associated with progressive disease course in primary sclerosing cholangitis. Sci Rep. 2018; 8:399. doi: 10.1038/s41598-017-18622-1.Tornai T., Tornai D., Sipeki N. et al. Loss of tolerance to gut immunity protein, glycoprotein 2 (GP2) is associated with progressive disease course in primary sclerosing cholangitis. Sci Rep. 2018; 8:399. doi: 10.1038/s41598-017-18622-1.Gathungu G., Kim M. O., Ferguson J. P. et al. Granulocyte-macrophage colony-stimulating factor autoantibodies: a marker of aggressive Crohn’s disease. In amm Bowel Dis. 2013; 19:1671-80. doi: 10.1097/MIB.0b013e318281f506.Gathungu G., Kim M. O., Ferguson J. P. et al. Granulocyte-macrophage colony-stimulating factor autoantibodies: a marker of aggressive Crohn’s disease. In amm Bowel Dis. 2013; 19:1671-80. doi: 10.1097/MIB.0b013e318281f506.Sipeki N., Davida L., Palyu E. et al. Prevalence, signi cance and predictive value of antiphospholipid antibodies in Crohn’s disease. World J Gastroenterol. 2015; 21:6952-64. doi: 10.3748/wjg.v21.i22.6952.Sipeki N., Davida L., Palyu E. et al. Prevalence, signi cance and predictive value of antiphospholipid antibodies in Crohn’s disease. World J Gastroenterol. 2015; 21:6952-64. doi: 10.3748/wjg.v21.i22.6952.Deutschmann C., Sowa M., Murugaiyan J. et al. Identi cation of chitinase-3-like protein 1 as a novel neutrophil antigenic target in Crohn’s disease. J Crohns Colitis. 2019; 13:894-904. doi: 10.1093/ecco-jcc/jjz012.Deutschmann C., Sowa M., Murugaiyan J. et al. Identi cation of chitinase-3-like protein 1 as a novel neutrophil antigenic target in Crohn’s disease. J Crohns Colitis. 2019; 13:894-904. doi: 10.1093/ecco-jcc/jjz012.Kovacs G., Sipeki N., Suga B. et al. Signi cance of serological markers in the disease course of ulcerative colitis in a prospective clinical cohort of patients. PLoS ONE. 2018; 13: e194166. doi: 10.1371/journal.pone.0194166.Kovacs G., Sipeki N., Suga B. et al. Signi cance of serological markers in the disease course of ulcerative colitis in a prospective clinical cohort of patients. PLoS ONE. 2018; 13: e194166. doi: 10.1371/journal.pone.0194166.Conrad K., Roggenbuck D., Laass M. W. Diagnosis and classi cation of ulcerative colitis. Autoimmun Rev. 2014; 13:463-6. doi: 10.1016/j.autrev.2014.01.028.Conrad K., Roggenbuck D., Laass M. W. Diagnosis and classi cation of ulcerative colitis. Autoimmun Rev. 2014; 13:463-6. doi: 10.1016/j.autrev.2014.01.028.Joossens M., Van Steen K., Branche J. et al. Familial aggregation and antimicrobial response dose-dependently a ect the risk for Crohn’s disease. In amm Bowel Dis. 2010; 16:58-67. doi: 10.1002/ibd.20985.Joossens M., Van Steen K., Branche J. et al. Familial aggregation and antimicrobial response dose-dependently a ect the risk for Crohn’s disease. In amm Bowel Dis. 2010; 16:58-67. doi: 10.1002/ibd.20985.Papp M., Lakatos P. L. Serological Studies in In ammatory Bowel Disease: How Important Are They? Curr Opin Gastroenterol. 2014; 30:359-64. doi: 10.1097/MOG.0000000000000076.Papp M., Lakatos P. L. Serological Studies in In ammatory Bowel Disease: How Important Are They? Curr Opin Gastroenterol. 2014; 30:359-64. doi: 10.1097/MOG.0000000000000076.Kaul A., Hut ess S., Liu L. et al. Serum anti- glycan antibody biomarkers for in ammatory bowel disease diagnosis and progression: a systematic review and meta-analysis. In amm Bowel Dis. 2012; 18:1872-84. doi: 10.1002/ibd.22862.Kaul A., Hut ess S., Liu L. et al. Serum anti- glycan antibody biomarkers for in ammatory bowel disease diagnosis and progression: a systematic review and meta-analysis. In amm Bowel Dis. 2012; 18:1872-84. doi: 10.1002/ibd.22862.Kuna A. T. Serological markers of in ammatory bowel disease. Biochem Med. 2013; 23:28-42. doi: 10.11613/BM.2013.006.Kuna A. T. Serological markers of in ammatory bowel disease. Biochem Med. 2013; 23:28-42. doi: 10.11613/BM.2013.006.Xiong Y., Wang G. Z., Zhou J. Q. et al. Serum antibodies to microbial antigens for Crohn’s disease progression: a meta-analysis. Eur J Gastroenterol Hepatol. 2014; 26:733-42. doi: 10.1097/MEG.0000000000000102.Xiong Y., Wang G. Z., Zhou J. Q. et al. Serum antibodies to microbial antigens for Crohn’s disease progression: a meta-analysis. Eur J Gastroenterol Hepatol. 2014; 26:733-42. doi: 10.1097/MEG.0000000000000102.Hamilton A.L., Kamm M. A., De Cruz P. et al. Serologic antibodies in relation to outcome in postoperative Crohn’s disease. J Gastroenterol Hepatol. 2017; 32:1195-203. doi: 10.1111/jgh.13677.Hamilton A.L., Kamm M. A., De Cruz P. et al. Serologic antibodies in relation to outcome in postoperative Crohn’s disease. J Gastroenterol Hepatol. 2017; 32:1195-203. doi: 10.1111/jgh.13677.Elkadri A.A., Stempak J. M., Walters T. D. et al. Serum antibodies associated with complex in ammatory bowel disease. In amm Bowel Dis. 2013; 19:1499-505. doi: 10.1097/MIB.0b013e318281f2a1.Elkadri A.A., Stempak J. M., Walters T. D. et al. Serum antibodies associated with complex in ammatory bowel disease. In amm Bowel Dis. 2013; 19:1499-505. doi: 10.1097/MIB.0b013e318281f2a1.Zhou G., Song Y., Yang W. et al. ASCA, ANCA, ALCA and many more: are they useful in the diagnosis of in ammatory bowel disease? Dig Dis. 2016; 34:90-7. doi: 10.1159/000 442934.Zhou G., Song Y., Yang W. et al. ASCA, ANCA, ALCA and many more: are they useful in the diagnosis of in ammatory bowel disease? Dig Dis. 2016; 34:90-7. doi: 10.1159/000 442934.Kugathasan S., Denson L. A., Walters T. D. et al. Prediction of complicated disease course for children newly diagnosed with Crohn’s disease: a multicentre inception cohort study. Lancet. 2017; 389:1710-18. doi: 10.1016/S0140-6736(17)30317-3.Kugathasan S., Denson L. A., Walters T. D. et al. Prediction of complicated disease course for children newly diagnosed with Crohn’s disease: a multicentre inception cohort study. Lancet. 2017; 389:1710-18. doi: 10.1016/S0140-6736(17)30317-3.Rieder F., Schleder S., Wolf A. et al. Association of the novel serologic anti-glycan antibodies anti-laminarin and anti-chitin with complicated Crohn’s disease behavior. In amm Bowel Dis. 2010; 16:263-74. doi: 10.1002/ibd.21046.Rieder F., Schleder S., Wolf A. et al. Association of the novel serologic anti-glycan antibodies anti-laminarin and anti-chitin with complicated Crohn’s disease behavior. In amm Bowel Dis. 2010; 16:263-74. doi: 10.1002/ibd.21046.Matsui M., Corey D. R. Non-coding RNAs as drug targets. Nat Rev Drug Discov. 2017; 16:167-79. doi: 10.1038/nrd.2016.117.Matsui M., Corey D. R. Non-coding RNAs as drug targets. Nat Rev Drug Discov. 2017; 16:167-79. doi: 10.1038/nrd.2016.117.Haberman Y., Benshoshan M., Di Segni A. et al. Long ncRNA landscape in the ileum of treatment- naive early-onset Crohn disease. In amm Bowel Dis. 2018; 24:346-60. doi: 10.1093/ibd/izx013.Haberman Y., Benshoshan M., Di Segni A. et al. Long ncRNA landscape in the ileum of treatment- naive early-onset Crohn disease. In amm Bowel Dis. 2018; 24:346-60. doi: 10.1093/ibd/izx013.Romakina V.V., Zhirov I. V., Nasonova S. N. et al. MicroRNAs as Biomarkers of Cardiovascular Diseases. Kardiologiia. 2018;58(1):66-71. (In Russ.) doi: 10.18087/cardio.2018.1.10083.@!@ Ромакина В. В., Жиров И. В., Насонова С. Н. и соавт. МикроРНК как биомаркеры сердечно-сосудистых заболеваний. Кардиология. 2018;58(1):66-71. doi:10.18087/cardio.2018.1.10083.Romakina V.V., Zhirov I. V., Nasonova S. N. et al. MicroRNAs as Biomarkers of Cardiovascular Diseases. Kardiologiia. 2018;58(1):66-71. (In Russ.) doi: 10.18087/cardio.2018.1.10083.@!@ Ромакина В. В., Жиров И. В., Насонова С. Н. и соавт. МикроРНК как биомаркеры сердечно-сосудистых заболеваний. Кардиология. 2018;58(1):66-71. doi:10.18087/cardio.2018.1.10083.Mishra P.J., Bertino J. R. MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine. Pharmacogenomics. 2009;10 (3):399-416. doi:10.2217/14622416.10.3.399.Mishra P.J., Bertino J. R. MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine. Pharmacogenomics. 2009;10 (3):399-416. doi:10.2217/14622416.10.3.399.Moret-Tatay I., Iborra M., Cerrillo E. et al. Possible biomarkers in blood for crohn’s disease: oxidative stress and micrornas- current evidences and further aspects to unravel. Oxid Med Cell Longev. 2016; 2016:2325162. doi: 10.1155/2016/2325162.Moret-Tatay I., Iborra M., Cerrillo E. et al. Possible biomarkers in blood for crohn’s disease: oxidative stress and micrornas- current evidences and further aspects to unravel. Oxid Med Cell Longev. 2016; 2016:2325162. doi: 10.1155/2016/2325162.Liu Y., Dong Y., Zhu X. et al. MiR- 155 inhibition ameliorates 2, 4, 6-Trinitrobenzenesulfonic acid (TNBS)-induced experimental colitis in rat via in uencing the di erentiation of Th17 cells by Jarid2.Int Immunopharmacol. 2018; 64:401-10. doi: 10.1016/j.intimp.2018.09.007.Liu Y., Dong Y., Zhu X. et al. MiR- 155 inhibition ameliorates 2, 4, 6-Trinitrobenzenesulfonic acid (TNBS)-induced experimental colitis in rat via in uencing the di erentiation of Th17 cells by Jarid2.Int Immunopharmacol. 2018; 64:401-10. doi: 10.1016/j.intimp.2018.09.007.Moein S., Vaghari-Tabari M., Qujeq D. et al. MiRNAs and in ammatory bowel disease: an interesting new story. J Cell Physiol. 2019; 234:3277-93. doi: 10.1002/jcp.27173.Moein S., Vaghari-Tabari M., Qujeq D. et al. MiRNAs and in ammatory bowel disease: an interesting new story. J Cell Physiol. 2019; 234:3277-93. doi: 10.1002/jcp.27173.Zahm A.M., Thayu M., Hand N. J. et al. Circulating MicroRNA is a biomarker of pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2011; 53:26-33. doi: 10.1097/MPG.0b013e31822200cc.Zahm A.M., Thayu M., Hand N. J. et al. Circulating MicroRNA is a biomarker of pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2011; 53:26-33. doi: 10.1097/MPG.0b013e31822200cc.Schonauen K., Le N., von Arnim U. et al. Circulating and Fecal microRNAs as biomarkers for in ammatory bowel diseases. In amm Bowel Dis. 2018; 24:1547-57. doi: 10.1093/ibd/izy046.Schonauen K., Le N., von Arnim U. et al. Circulating and Fecal microRNAs as biomarkers for in ammatory bowel diseases. In amm Bowel Dis. 2018; 24:1547-57. doi: 10.1093/ibd/izy046.Thorlacius-Ussing G., Schnack N. B., Andersen V. et al. Expression and localization of miR-21 and miR-126 in mucosal tissue from patients with in ammatory bowel disease. In amm Bowel Dis. 2017; 23:739-52. doi: 10.1097/MIB.0000000000001086.Thorlacius-Ussing G., Schnack N. B., Andersen V. et al. Expression and localization of miR-21 and miR-126 in mucosal tissue from patients with in ammatory bowel disease. In amm Bowel Dis. 2017; 23:739-52. doi: 10.1097/MIB.0000000000001086.Zacharopoulou E., Gazouli M., Tzouvala M. et al. The contribution of long non-coding RNAs in in ammatory bowel diseases. Dig Liver Dis. 2017; 49:1067-72. doi: 10.1016/j.dld.2017.08.003.Zacharopoulou E., Gazouli M., Tzouvala M. et al. The contribution of long non-coding RNAs in in ammatory bowel diseases. Dig Liver Dis. 2017; 49:1067-72. doi: 10.1016/j.dld.2017.08.003.Chen T., Xue H., Lin R., Huang Z. MiR-34c and PlncRNA1 mediated the function of intestinal epithelial barrier by regulating tight junction proteins in in ammatory bowel disease. Biochem Biophys Res Commun. 2017; 486:6-13. doi: 10.1016/j.bbrc.2017.01.115.Chen T., Xue H., Lin R., Huang Z. MiR-34c and PlncRNA1 mediated the function of intestinal epithelial barrier by regulating tight junction proteins in in ammatory bowel disease. Biochem Biophys Res Commun. 2017; 486:6-13. doi: 10.1016/j.bbrc.2017.01.115.Wu F., Huang Y., Dong F., Kwon J. H. Ulcerative colitis-associated long noncoding RNA, BC012900, regulates intestinal epithelial cell apoptosis. In amm Bowel Dis. 2016; 22:782-95. doi: 10.1097/MIB.0000000000000691.Wu F., Huang Y., Dong F., Kwon J. H. Ulcerative colitis-associated long noncoding RNA, BC012900, regulates intestinal epithelial cell apoptosis. In amm Bowel Dis. 2016; 22:782-95. doi: 10.1097/MIB.0000000000000691.Chen D., Liu J., Zhao H. Y. et al. Plasma long noncoding RNA expression pro le identi ed by microarray in patients with Crohn’s disease. World J Gastroenterol. 2016; 22:4716-31. doi: 10.3748/wjg.v22.i19.4716.Chen D., Liu J., Zhao H. Y. et al. Plasma long noncoding RNA expression pro le identi ed by microarray in patients with Crohn’s disease. World J Gastroenterol. 2016; 22:4716-31. doi: 10.3748/wjg.v22.i19.4716.Kumar S., Williams D., Sur S. et al. Role of ow- sensitive microRNAs and long noncoding RNAs in vascular dysfunction and atherosclerosis. Vascul Pharmacol. 2019; 114:76-92. doi: 10.1016/j.vph.2018.10.001.Kumar S., Williams D., Sur S. et al. Role of ow- sensitive microRNAs and long noncoding RNAs in vascular dysfunction and atherosclerosis. Vascul Pharmacol. 2019; 114:76-92. doi: 10.1016/j.vph.2018.10.001.Williams H.R., Willsmore J. D., Cox I. J. et al. Serum metabolic pro ling in in ammatory bowel disease. Dig Dis Sci. 2012; 57:2157-65. doi: 10.1007/s10620-012-2127-2.Williams H.R., Willsmore J. D., Cox I. J. et al. Serum metabolic pro ling in in ammatory bowel disease. Dig Dis Sci. 2012; 57:2157-65. doi: 10.1007/s10620-012-2127-2.Ooi M., Nishiumi S., Yoshie T. et al. GC/MS-based pro ling of amino acids and TCA cycle- related molecules in ulcerative colitis. In amm Res. 2011; 60:831-40. doi: 10.1007/s00011-011-0340-7.Ooi M., Nishiumi S., Yoshie T. et al. GC/MS-based pro ling of amino acids and TCA cycle- related molecules in ulcerative colitis. In amm Res. 2011; 60:831-40. doi: 10.1007/s00011-011-0340-7.Scoville E.A., Allaman M. M., Brown C. T. et al. Alterations in lipid, amino acid, and energy metabolism distinguish Crohn’s disease from ulcerative colitis and control subjects by serum metabolomic pro ling. Metabolomics. 2018; 14:17. doi: 10.1007/s11306-017-1311-y.Scoville E.A., Allaman M. M., Brown C. T. et al. Alterations in lipid, amino acid, and energy metabolism distinguish Crohn’s disease from ulcerative colitis and control subjects by serum metabolomic pro ling. Metabolomics. 2018; 14:17. doi: 10.1007/s11306-017-1311-y.Kolho K., Pessia A., Jaakkola T. et al. Faecal and serum metabolomics in paediatric in ammatory bowel disease. J Crohn’s Colitis. 2016; 11:321-34. doi: 10.1093/ecco-jcc/jjw158.Kolho K., Pessia A., Jaakkola T. et al. Faecal and serum metabolomics in paediatric in ammatory bowel disease. J Crohn’s Colitis. 2016; 11:321-34. doi: 10.1093/ecco-jcc/jjw158.Meuwis M.A., Fillet M., Geurts P. et al. Biomarker discovery for in ammatory bowel disease, using proteomic serum pro ling. Biochem Pharmacol. 2007; 73:1422-33. doi: 10.1016/j.bcp.2006.12.019.Meuwis M.A., Fillet M., Geurts P. et al. Biomarker discovery for in ammatory bowel disease, using proteomic serum pro ling. Biochem Pharmacol. 2007; 73:1422-33. doi: 10.1016/j.bcp.2006.12.019.Zhang F., Xu C., Ning L. et al. Correction: exploration of serum proteomic pro ling and diagnostic model that di erentiate Crohn’s disease and intestinal tuberculosis. PLoS ONE. 2019; 14: e212300. doi: 10.1371/journal.pone.0212300.Zhang F., Xu C., Ning L. et al. Correction: exploration of serum proteomic pro ling and diagnostic model that di erentiate Crohn’s disease and intestinal tuberculosis. PLoS ONE. 2019; 14: e212300. doi: 10.1371/journal.pone.0212300.Drobin K., Assadi G., Hong M. G. et al. Targeted analysis of serum proteins encoded at known in ammatory bowel disease risk loci. In amm Bowel Dis. 2019; 25:306-16. doi: 10.1093/ibd/izy326.Drobin K., Assadi G., Hong M. G. et al. Targeted analysis of serum proteins encoded at known in ammatory bowel disease risk loci. In amm Bowel Dis. 2019; 25:306-16. doi: 10.1093/ibd/izy326.Verstockt S., Verstockt B., Vermeire S. Oncostatin M as a new diagnostic, prognostic and therapeutic target in In ammatory Bowel Disease (IBD). Expert Opin Ther Targets. 2019; 23:943-54. doi: 10.1080/ 14728222.2019.1677608.Verstockt S., Verstockt B., Vermeire S. Oncostatin M as a new diagnostic, prognostic and therapeutic target in In ammatory Bowel Disease (IBD). Expert Opin Ther Targets. 2019; 23:943-54. doi: 10.1080/ 14728222.2019.1677608.West N.R., Hegazy A. N., Owens B. et al. Oncostatin M drives intestinal in ammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with in ammatory bowel disease. Nat Med. 2017; 23:579-89. doi: 10.1038/nm.4307.West N.R., Hegazy A. N., Owens B. et al. Oncostatin M drives intestinal in ammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with in ammatory bowel disease. Nat Med. 2017; 23:579-89. doi: 10.1038/nm.4307.Frol’Ova L., Smetana K. J., Borovska D. et al. Detection of galectin-3 in patients with in ammatory bowel diseases: new serum marker of active forms of IBD? In amm Res. 2009; 58:503-12. doi: 10.1007/s00011-009-0016-8.Frol’Ova L., Smetana K. J., Borovska D. et al. Detection of galectin-3 in patients with in ammatory bowel diseases: new serum marker of active forms of IBD? In amm Res. 2009; 58:503-12. doi: 10.1007/s00011-009-0016-8.Yu T.B., Dodd S., Yu L., Subramanian S. Serum galectins as potential biomarkers of in ammatory bowel diseases. PLOS ONE. 2020; 15: e227306. doi: 10.1371/journal.pone.0227306.Yu T.B., Dodd S., Yu L., Subramanian S. Serum galectins as potential biomarkers of in ammatory bowel diseases. PLOS ONE. 2020; 15: e227306. doi: 10.1371/journal.pone.0227306.Rieder F., de Bruyn J. R., Pham B. T. et al. Results of the 4th scienti c workshop of the ECCO (Group II): markers of intestinal brosis in in ammatory bowel disease. J Crohns Colitis. 2014; 8:1166-78. doi: 10.1016/j.crohns.2014.03.009.Rieder F., de Bruyn J. R., Pham B. T. et al. Results of the 4th scienti c workshop of the ECCO (Group II): markers of intestinal brosis in in ammatory bowel disease. J Crohns Colitis. 2014; 8:1166-78. doi: 10.1016/j.crohns.2014.03.009.Allan A., Wyke J., Allan R. N. et al. Plasma bronectin in Crohn’s disease. Gut. 1989; 30:627-33. doi: 10.1136/gut.30.5.627.Allan A., Wyke J., Allan R. N. et al. Plasma bronectin in Crohn’s disease. Gut. 1989; 30:627-33. doi: 10.1136/gut.30.5.627.Verspaget H.W., Biemond I., Allaart C. F. et al. Assessment of plasma bronectin in Crohn’s disease. Hepatogastroenterology. 1991; 38:231-4.Verspaget H.W., Biemond I., Allaart C. F. et al. Assessment of plasma bronectin in Crohn’s disease. Hepatogastroenterology. 1991; 38:231-4.Koutroubakis I.E., Petinaki E., Dimoulios P. et al. Serum laminin and collagen IV in in ammatory bowel disease. J Clin Pathol. 2003; 56:817-20. doi: 10.1136/jcp.56.11.817.Koutroubakis I.E., Petinaki E., Dimoulios P. et al. Serum laminin and collagen IV in in ammatory bowel disease. J Clin Pathol. 2003; 56:817-20. doi: 10.1136/jcp.56.11.817.Matusiewicz M., Neubauer K., Mierzchala-Pasierb M. et al. Matrix metalloproteinase-9: its interplay with angiogenic factors in in ammatory bowel diseases. Dis Mark. 2014; 2014:643645. doi: 10.1155/2014/643645.Matusiewicz M., Neubauer K., Mierzchala-Pasierb M. et al. Matrix metalloproteinase-9: its interplay with angiogenic factors in in ammatory bowel diseases. Dis Mark. 2014; 2014:643645. doi: 10.1155/2014/643645.Kapsoritakis A.N., Kapsoritaki A. I., Davidi I. P. et al. Imbalance of tissue inhibitors of metalloproteinases (TIMP) - 1 and - 4 serum levels, in patients with in ammatory bowel disease. BMC Gastroenterol. 2008; 8:55. doi: 10.1186/1471-230X-8-55.Kapsoritakis A.N., Kapsoritaki A. I., Davidi I. P. et al. Imbalance of tissue inhibitors of metalloproteinases (TIMP) - 1 and - 4 serum levels, in patients with in ammatory bowel disease. BMC Gastroenterol. 2008; 8:55. doi: 10.1186/1471-230X-8-55.Carbone F., Bodini G., Brunacci M. et al. Reduction in TIMP-2 serum levels predicts remission of in ammatory bowel diseases. Eur J Clin Invest. 2018; 48: e13002. doi: 10.1111/eci.13002.Carbone F., Bodini G., Brunacci M. et al. Reduction in TIMP-2 serum levels predicts remission of in ammatory bowel diseases. Eur J Clin Invest. 2018; 48: e13002. doi: 10.1111/eci.13002.De Simone M., Ciulla M. M., Cio U. et al. E ects of surgery on peripheral N-terminal propeptide of type III procollagen in patients with Crohn’s disease. J Gastrointest Surg. 2007; 11:1361-4. doi: 10.1007/s11605-007-0233-9.De Simone M., Ciulla M. M., Cio U. et al. E ects of surgery on peripheral N-terminal propeptide of type III procollagen in patients with Crohn’s disease. J Gastrointest Surg. 2007; 11:1361-4. doi: 10.1007/s11605-007-0233-9.Giu rida P., Pinzani M., Corazza G. R., Di Sabatino A. Biomarkers of intestinal brosis - one step towards clinical trials for stricturing in ammatory bowel disease. United European Gastroenterol J. 2016; 4:523-30. doi: 10.1177/2050640616640160.Giu rida P., Pinzani M., Corazza G. R., Di Sabatino A. Biomarkers of intestinal brosis - one step towards clinical trials for stricturing in ammatory bowel disease. United European Gastroenterol J. 2016; 4:523-30. doi: 10.1177/2050640616640160.Ballengee C.R., Stidham R. W., Liu C., et al. Association Between Plasma Level of Collagen Type III Alpha 1 Chain and Development of Strictures in Pediatric Patients With Crohn’s Disease. Clin Gastroenterol Hepatol. 2019 Aug;17(9):1799-1806. doi: 10.1016/j.cgh.2018.09.008.Ballengee C.R., Stidham R. W., Liu C., et al. Association Between Plasma Level of Collagen Type III Alpha 1 Chain and Development of Strictures in Pediatric Patients With Crohn’s Disease. Clin Gastroenterol Hepatol. 2019 Aug;17(9):1799-1806. doi: 10.1016/j.cgh.2018.09.008.Di Sabatino A., Ciccocioppo R., Armellini E. et al. Serum bFGF and VEGF correlate respectively with bowel wall thickness and intramural blood ow in Crohn’s disease. In amm Bowel Dis. 2004; 10:573-7. doi: 10.1097/00054725-200409000-00011.Di Sabatino A., Ciccocioppo R., Armellini E. et al. Serum bFGF and VEGF correlate respectively with bowel wall thickness and intramural blood ow in Crohn’s disease. In amm Bowel Dis. 2004; 10:573-7. doi: 10.1097/00054725-200409000-00011.Erzin Y., Uzun H., Karatas A., Celik A. F. Serum YKL-40 as a marker of disease activity and stricture formation in patients with Crohn’s disease. J Gastroenterol Hepatol. 2008; 23: e357-62. doi: 10.1111/j.1440-1746.2007.05121.x.Erzin Y., Uzun H., Karatas A., Celik A. F. Serum YKL-40 as a marker of disease activity and stricture formation in patients with Crohn’s disease. J Gastroenterol Hepatol. 2008; 23: e357-62. doi: 10.1111/j.1440-1746.2007.05121.x.Algaba A., Linares P. M., Encarnacion F. M. et al. The e ects of in iximab or adalimumab on vascular endothelial growth factor and angiopoietin 1 angiogenic factor levels in in ammatory bowel disease: serial observations in 37 patients. In amm Bowel Dis. 2014; 20:695-702. doi: 10.1097/MIB.0000000000000004.Algaba A., Linares P. M., Encarnacion F. M. et al. The e ects of in iximab or adalimumab on vascular endothelial growth factor and angiopoietin 1 angiogenic factor levels in in ammatory bowel disease: serial observations in 37 patients. In amm Bowel Dis. 2014; 20:695-702. doi: 10.1097/MIB.0000000000000004.Zidar N., Bostjancic E., Jerala M. et al. Down-regulation of microRNAs of the miR-200 family and up- regulation of Snail and Slug in in ammatory bowel diseases - hallmark of epithelial-mesenchymal transition. J Cell Mol Med. 2016; 20:1813-20. doi: 10.1111/jcmm.12869.Zidar N., Bostjancic E., Jerala M. et al. Down-regulation of microRNAs of the miR-200 family and up- regulation of Snail and Slug in in ammatory bowel diseases - hallmark of epithelial-mesenchymal transition. J Cell Mol Med. 2016; 20:1813-20. doi: 10.1111/jcmm.12869.Lewis A., Nijhuis A., Mehta S. et al.Intestinal Fibrosis in Crohn’s Disease. In amm Bowel Dis. 2015; 21:1141-50. doi: 10.1097/MIB.0000000000000298.Lewis A., Nijhuis A., Mehta S. et al.Intestinal Fibrosis in Crohn’s Disease. In amm Bowel Dis. 2015; 21:1141-50. doi: 10.1097/MIB.0000000000000298.Nijhuis A., Biancheri P., Lewis A. et al. In Crohn’s disease brosis-reduced expression of the miR-29 family enhances collagen expression in intestinal broblasts. Clin Sci. 2014; 127:341-50. doi: 10.1042/CS20140048.Nijhuis A., Biancheri P., Lewis A. et al. In Crohn’s disease brosis-reduced expression of the miR-29 family enhances collagen expression in intestinal broblasts. Clin Sci. 2014; 127:341-50. doi: 10.1042/CS20140048.Lewis A., Mehta S., Hanna L. N. et al. Low serum levels of MicroRNA-19 are associated with a stricturing Crohn’s disease phenotype. In amm Bowel Dis. 2015; 21:1926-34. doi: 10.1097/MIB.0000000000000443.Lewis A., Mehta S., Hanna L. N. et al. Low serum levels of MicroRNA-19 are associated with a stricturing Crohn’s disease phenotype. In amm Bowel Dis. 2015; 21:1926-34. doi: 10.1097/MIB.0000000000000443.Paul S., Boschetti G., Rinaudo-Gaujous M. et al. Association of anti-glycan antibodies and in ammatory bowel disease course. J Crohns Colitis. 2015; 9:445-51. doi: 10.1093/ecco-jcc/jjv063.Paul S., Boschetti G., Rinaudo-Gaujous M. et al. Association of anti-glycan antibodies and in ammatory bowel disease course. J Crohns Colitis. 2015; 9:445-51. doi: 10.1093/ecco-jcc/jjv063.Kevans D., Waterman M., Milgrom R. et al. Serological markers associated with disease behavior and response to anti- tumor necrosis factor therapy in ulcerative colitis. J Gastroenterol Hepatol. 2015; 30:64-70. doi: 10.1111/jgh.12661.Kevans D., Waterman M., Milgrom R. et al. Serological markers associated with disease behavior and response to anti- tumor necrosis factor therapy in ulcerative colitis. J Gastroenterol Hepatol. 2015; 30:64-70. doi: 10.1111/jgh.12661.Caneparo V., Pastorelli L., Pisani L. F. et al. Distinct Anti-IFI16 and anti-GP2 antibodies in in ammatory bowel disease and their variation with in iximab therapy. In amm Bowel Dis. 2016; 22:2977-87. doi: 10.1097/MIB.0000000000 000926.Caneparo V., Pastorelli L., Pisani L. F. et al. Distinct Anti-IFI16 and anti-GP2 antibodies in in ammatory bowel disease and their variation with in iximab therapy. In amm Bowel Dis. 2016; 22:2977-87. doi: 10.1097/MIB.0000000000 000926.Sachar D. B. Role of biomarkers in the study and management of in ammatory bowel disease: a “nonsystematic” review. In amm Bowel Dis. 2014; 20:2511-18. doi: 10.1097/MIB.0000000000000135.Sachar D. B. Role of biomarkers in the study and management of in ammatory bowel disease: a “nonsystematic” review. In amm Bowel Dis. 2014; 20:2511-18. doi: 10.1097/MIB.0000000000000135.Solem C.A., Loftus E. J., Tremaine W. J. et al. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in in ammatory bowel disease. In amm Bowel Dis. 2005; 11:707-12. doi: 10.1097/01.MIB.0000173271.18319.53.Solem C.A., Loftus E. J., Tremaine W. J. et al. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in in ammatory bowel disease. In amm Bowel Dis. 2005; 11:707-12. doi: 10.1097/01.MIB.0000173271.18319.53.Tran D.H., Wang J., Ha C. et al. Circulating cathelicidin levels correlate with mucosal disease activity in ulcerative colitis, risk of intestinal stricture in Crohn’s disease, and clinical prognosis in in ammatory bowel disease. BMC Gastroenterol. 2017; 17:63. doi: 10.1186/s12876-017-0619-4.Tran D.H., Wang J., Ha C. et al. Circulating cathelicidin levels correlate with mucosal disease activity in ulcerative colitis, risk of intestinal stricture in Crohn’s disease, and clinical prognosis in in ammatory bowel disease. BMC Gastroenterol. 2017; 17:63. doi: 10.1186/s12876-017-0619-4.Nakov R., Velikova T., Nakov V. et al. Serum trefoil factor 3 predicts disease activity in patients with ulcerative colitis. Eur Rev Med Pharmacol Sci. 2019; 23:788. doi: 10.26355/eurrev_201901_16893.Nakov R., Velikova T., Nakov V. et al. Serum trefoil factor 3 predicts disease activity in patients with ulcerative colitis. Eur Rev Med Pharmacol Sci. 2019; 23:788. doi: 10.26355/eurrev_201901_16893.Lacruz-Guzman D., Torres-Moreno D., Pedrero F. et al. In uence of polymorphisms and TNF and IL1beta serum concentration on the in iximab response in Crohn’s disease and ulcerative colitis. Eur J Clin Pharmacol. 2013; 69:431-8. doi: 10.1007/s00228-012-1389-0.Lacruz-Guzman D., Torres-Moreno D., Pedrero F. et al. In uence of polymorphisms and TNF and IL1beta serum concentration on the in iximab response in Crohn’s disease and ulcerative colitis. Eur J Clin Pharmacol. 2013; 69:431-8. doi: 10.1007/s00228-012-1389-0.Billiet T., Cleynen I., Ballet V. et al. Evolution of cytokines and in ammatory biomarkers during in iximab induction therapy and the impact of in ammatory burden on primary response in patients with Crohn’s disease. Scand J Gastroenterol. 2017; 52:1086-92. doi: 10.1080/00365521.2017.1339825.Billiet T., Cleynen I., Ballet V. et al. Evolution of cytokines and in ammatory biomarkers during in iximab induction therapy and the impact of in ammatory burden on primary response in patients with Crohn’s disease. Scand J Gastroenterol. 2017; 52:1086-92. doi: 10.1080/00365521.2017.1339825.Feng T., Chen B., Li L. et al. Serum interleukin 9 levels predict disease severity and the clinical e cacy of in iximab in patients with Crohn’s disease. In amm Bowel Dis. 2017; 23:1817-24. doi: 10.1097/MIB.0000000000001172.Feng T., Chen B., Li L. et al. Serum interleukin 9 levels predict disease severity and the clinical e cacy of in iximab in patients with Crohn’s disease. In amm Bowel Dis. 2017; 23:1817-24. doi: 10.1097/MIB.0000000000001172.Baird A.C., Mallon D., Radford-Smith G. et al. Dysregulation of innate immunity in ulcerative colitis patients who fail anti-tumor necrosis factor therapy. World J Gastroenterol. 2016; 22:9104. doi: 10.3748/wjg.v22.i41.9104.Baird A.C., Mallon D., Radford-Smith G. et al. Dysregulation of innate immunity in ulcerative colitis patients who fail anti-tumor necrosis factor therapy. World J Gastroenterol. 2016; 22:9104. doi: 10.3748/wjg.v22.i41.9104.Magnusson M.K., Strid H., Isaksson S. et al. Response to in iximab therapy in ulcerative colitis is associated with decreased monocyte activation, reduced CCL2 expression and downregulation of Tenascin C. J Crohns Colitis. 2015; 9:56-65. doi: 10.1093/ecco-jcc/jju008.Magnusson M.K., Strid H., Isaksson S. et al. Response to in iximab therapy in ulcerative colitis is associated with decreased monocyte activation, reduced CCL2 expression and downregulation of Tenascin C. J Crohns Colitis. 2015; 9:56-65. doi: 10.1093/ecco-jcc/jju008.Obraztsov I.V., Shirokikh K. E., Obraztsova O. I. et al. Multiple cytokine pro ling: a new model to predict response to tumor necrosis factor antagonists in ulcerative colitis patients. In amm Bowel Dis. 2019; 25:524-31. doi: 10.1093/ibd/izy358.Obraztsov I.V., Shirokikh K. E., Obraztsova O. I. et al. Multiple cytokine pro ling: a new model to predict response to tumor necrosis factor antagonists in ulcerative colitis patients. In amm Bowel Dis. 2019; 25:524-31. doi: 10.1093/ibd/izy358.Sands B.E., Chen J., Feagan B. G. et al. E cacy and safety of MEDI2070, an antibody against interleukin 23, in patients with moderate to severe Crohn’s disease: a phase 2a study. Gastroenterology. 2017; 153:77-86. doi: 10.1053/j.gastro.2017.03.049.Sands B.E., Chen J., Feagan B. G. et al. E cacy and safety of MEDI2070, an antibody against interleukin 23, in patients with moderate to severe Crohn’s disease: a phase 2a study. Gastroenterology. 2017; 153:77-86. doi: 10.1053/j.gastro.2017.03.049.Bertani L., Baglietto L., Antonioli L., et al. Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients. Br J Clin Pharmacol. 2020 Jul;86(7):1296-1305. doi: 10.1111/bcp.14235.Bertani L., Baglietto L., Antonioli L., et al. Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients. Br J Clin Pharmacol. 2020 Jul;86(7):1296-1305. doi: 10.1111/bcp.14235.Louis E., Belaiche J., van Kemseke C. et al. A high serum concentration of interleukin-6 is predictive of relapse in quiescent Crohn’s disease. Eur J Gastroenterol Hepatol. 1997; 9:939-44. doi: 10.1097/00042737-199710000-00004.Louis E., Belaiche J., van Kemseke C. et al. A high serum concentration of interleukin-6 is predictive of relapse in quiescent Crohn’s disease. Eur J Gastroenterol Hepatol. 1997; 9:939-44. doi: 10.1097/00042737-199710000-00004.Luo J., Wang Y., Lan D. et al. Di erential expression of serum microRNAs in glucocorticoid-resistant patients with ulcerative colitis.Int J Clin Exp Pathol. 2018; 11:936-946.Luo J., Wang Y., Lan D. et al. Di erential expression of serum microRNAs in glucocorticoid-resistant patients with ulcerative colitis.Int J Clin Exp Pathol. 2018; 11:936-946.Wang S., Hou Y., Chen W. et al. KIF9AS1, LINC01272 and DIO3OS lncRNAs as novel biomarkers for in ammatory bowel disease. Mol Med Rep. 2018; 17:2195-202. doi: 10.3892/mmr.2017.8118.Wang S., Hou Y., Chen W. et al. KIF9AS1, LINC01272 and DIO3OS lncRNAs as novel biomarkers for in ammatory bowel disease. Mol Med Rep. 2018; 17:2195-202. doi: 10.3892/mmr.2017.8118.Hisamatsu T., Okamoto S., Hashimoto M. et al. Novel, objective, multivariate biomarkers composed of plasma amino acid pro les for the diagnosis and assessment of in ammatory bowel disease. PLoS ONE. 2012; 7: e31131. doi: 10.1371/journal.pone.0031131.Hisamatsu T., Okamoto S., Hashimoto M. et al. Novel, objective, multivariate biomarkers composed of plasma amino acid pro les for the diagnosis and assessment of in ammatory bowel disease. PLoS ONE. 2012; 7: e31131. doi: 10.1371/journal.pone.0031131.Cleynen I., Boucher G., Jostins L. et al. Inherited determinants of Crohn’s disease and ulcerative colitis phenotypes: a genetic association study. Lancet. 2016; 387:156-67. doi: 10.1016/S0140-6736(15)00465-1.Cleynen I., Boucher G., Jostins L. et al. Inherited determinants of Crohn’s disease and ulcerative colitis phenotypes: a genetic association study. Lancet. 2016; 387:156-67. doi: 10.1016/S0140-6736(15)00465-1.Nielsen O.H., Rejnmark L., Moss A. C. Role of Vitamin D in the Natural History of Inflammatory Bowel Disease. J Crohns Colitis. 2018 May 25;12(6):742-752. doi: 10.1093/ecco-jcc/jjy025.Nielsen O.H., Rejnmark L., Moss A. C. Role of Vitamin D in the Natural History of Inflammatory Bowel Disease. J Crohns Colitis. 2018 May 25;12(6):742-752. doi: 10.1093/ecco-jcc/jjy025.Zator Z.A., Cantu S. M., Konijeti G. G. et al. Pretreatment 25-hydroxyvitamin D levels and durability of anti-tumor necrosis factor-alpha therapy in in ammatory bowel diseases. J Parenter Enteral Nutr. 2014; 38:385-91. doi: 10.1177/0148607113504002.Zator Z.A., Cantu S. M., Konijeti G. G. et al. Pretreatment 25-hydroxyvitamin D levels and durability of anti-tumor necrosis factor-alpha therapy in in ammatory bowel diseases. J Parenter Enteral Nutr. 2014; 38:385-91. doi: 10.1177/0148607113504002.Santos-Antunes J., Nunes A. C., Lopes S., Macedo G. The relevance of vitamin D and antinuclear antibodies in patients with in ammatory bowel disease under anti-TNF treatment: a prospective study. In amm Bowel Dis. 2016; 22:1101-6. doi: 10.1097/MIB.0000000000000697.Santos-Antunes J., Nunes A. C., Lopes S., Macedo G. The relevance of vitamin D and antinuclear antibodies in patients with in ammatory bowel disease under anti-TNF treatment: a prospective study. In amm Bowel Dis. 2016; 22:1101-6. doi: 10.1097/MIB.0000000000000697.Reich K.M., Fedorak R. N., Madsen K., Kroeker KI. Role of vitamin D in in iximab-induced remission in adult patients with Crohn’s Disease. In amm Bowel Dis. 2016; 22:92-9. doi: 10.1097/MIB.0000000000000588.Reich K.M., Fedorak R. N., Madsen K., Kroeker KI. Role of vitamin D in in iximab-induced remission in adult patients with Crohn’s Disease. In amm Bowel Dis. 2016; 22:92-9. doi: 10.1097/MIB.0000000000000588.Stidham R.W., Wu J., Shi J., Lubman D. M., Higgins P. D. Serum Glycoproteome Profiles for Distinguishing Intestinal Fibrosis from Inflammation in Crohn’s Disease. PLoS One. 2017 Jan 23;12(1): e0170506. doi: 10.1371/journal.pone.0170506.Stidham R.W., Wu J., Shi J., Lubman D. M., Higgins P. D. Serum Glycoproteome Profiles for Distinguishing Intestinal Fibrosis from Inflammation in Crohn’s Disease. PLoS One. 2017 Jan 23;12(1): e0170506. doi: 10.1371/journal.pone.0170506.

The authors declare that there are no conflicts of interest present.